Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children16510.24287/1726-1708-2016-15-3-19-22HEMATOLOGYГЕМАТОЛОГИЯSecondary prevention of hemorrhagic complications and pharmacokinetics of factor VIII in children with severe hemophilia AПрофилактика кровотечений и фармакокинетика фактора свертывания крови VIII у детей с тяжелой гемофилией АDmitrievVyacheslav V.ДмитриевВячеслав Васильевич
Russian Federation
dmitrievhaematol@mail.ruVolkovaLudmila I.ВолковаЛюдмила Ивановна
Russian Federation
luidmila_volkova@mail.ruDmitrievEvgeniy V.ДмитриевЕвгений Вячеславович
Russian Federation
Republican Scientific Centre of Pediatric Oncology, Hematology and Immunology, Ministry of HealthРеспубликанский научно-практический центр детской онкологии, гематологии и иммунологии Минздрава Республики БеларусьBelarusian Medical Academy of Post-Graduate Education Ministry of HealthБелорусская медицинская академия последипломного образования Минздрава Республики Беларусь19092016153192219092018Copyright ©; 2016, «D. Rogachev NMRCPHOI»Copyright ©; 2016, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2016«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/165

Individual selection of dose and calculation of ratio for prevention of the introduction of the concentrate of coagulation factor VIII 23 patients with severe hemophilia A carried out the pharmacokinetic study. The half-life of exogenous factor VIII is 12 hours, registered in 12 (52%) patients, 7 boys (30%) - the half-life of factor VIII was 18 hours, in 4 (18%) children - 11 hours. Individual pharmacokinetic calculations allowed to carry out secondary prevention of spontaneous bleeding with multiplicity systematic introduction of a concentrate of coagulation factor VIII in 72, 96, or 48 hours, respectively, without bleeding complications. The combined change in parameters such as higher clearance (Cl) to 5,3 ml х kg-1 х hour-1, volume of distribution (Vd) to 79.0 ml х kg-1 with the decline in the normalized measure of the area under the curve (AUCnorm) to 14.7 ml-1 х h х kg and the recovery index (Recovery in vivo) to 1.27 % / ME х kg-1 and half-life (T/) to 11.0 hours, characterizes a type of inhibitory response to the introduction of the concentrate of coagulation factor VIII.

вторичная профилактика кровотеченийгемофилия Адетифактор VIIIфармакокинетикаhemophilia Achildrensecondary prevention of bleedingfactor VIIIpharmacokineticsAhlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthopaedica Scand. 1965;(Suppl 77):1-98.Nilsson IM, Blomback M, Ahlberg A. Our experience in Sweden with prophylaxis on haemophilia. Proceedings of the 5th Congress of the World Federation of Hemophilia, Montreal 1968; Bibl Haematol, No. 34. New York: Karger, 1970;111 -24.Björkman S. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia. 2003;9(Suppl. 1):101-8; discussion 109-10.Collins PW, Blanchette VS, Fischer K, Björkman S, Oh M, Fritsch S, et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009;7(3): 413-20.Collins PW, Fischer K, Morfini M, Blanchette VS, Björkman S; International Prophylaxis Study Group Pharmacokinetics Expert Working Group. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia. 2011;17(1):2-10.Björkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet. 2001 ;40(11): 815-32.Björkman S, Oh M, Spotts G, Schroth P, Fritsch S, Ewenstein BM, et al. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood. 2012;119(2):612-8.Hay CR, Broun S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitots: a guideline from the United Kingdom Hemophilia Centre Doctors Organisation. Br J Haematol. 2006; 133(6) :591 -605.Collins PW, Björkman S, Fischer K, Blanchette V, Oh M, Schroth P, et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost. 2010 Feb;8(2):269-75. doi: 10.1111/j.1538-7836. 2009.03703.x. Epub 2009 Nov 23.Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Thromb Haemost. 1991;66(3):384-6.Lee M, Morfini M, Schulman S, Ingerslev J; Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Scientific and Standardization Committee Communication. The design and analysis of pharmacokinetic studies of coagulation Factors. On behalf of the Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Available at: http://c.ymcdn.com/sites/www.isth.org/resource/ group/d4a6f49a-f4ec-450f-9e0f-7be9f0c2ab2e/official_communications/ fviiipharmaco.pdf.